Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced a $175 million underwritten public offering of its common stock, with an option for underwriters to purchase an additional $26.25 million of shares. Goldman Sachs & Co. LLC, Jefferies, and TD Cowen serve as joint book‑running managers, while TPG Capital BD, LLC acts as co‑manager.
The proceeds will be directed toward general corporate purposes, including funding ongoing clinical trials, research and development, general and administrative expenses, and capital expenditures. The company’s recent financial statements show a negative levered free cash flow of $149.63 million over the last twelve months, and a net loss of $38.8 million in Q4 2025, underscoring the need for additional capital to sustain its clinical pipeline through the first half of 2028.
The offering announcement coincided with the release of interim futility analysis data from the pivotal Phase 2 ALPHA3 trial of cema‑cel in first‑line consolidation for large B‑cell lymphoma. The data revealed a 58.3 % minimal residual disease clearance rate in the cema‑cel arm versus 16.7 % in the observation arm, a 41.6 percentage‑point absolute difference that bolstered confidence in the lead product and likely contributed to investor enthusiasm.
Following the announcement, several analysts upgraded their outlooks and raised price targets. Baird’s Jack Allen moved the rating to “Outperform” and increased the target from $7.00 to $9.00; Citizens raised its target from $5.00 to $8.00; Piper Sandler had previously lifted its target from $7 to $8; and Jefferies issued a “Buy” rating. These upgrades reflect the market’s positive reception to the clinical data and the company’s ability to raise capital to support its development plans.
In a March 12, 2026 update, President and CEO David Chang noted that Allogene is “approaching a pivotal inflection point” with the ALPHA3 data “just weeks away.” He emphasized the company’s focus on disciplined execution and delivering transformative data across its portfolio, highlighting the strategic importance of the new capital to sustain its growth trajectory.
The offering is being made pursuant to a shelf registration statement filed with the SEC, declared effective on April 25, 2024. The registration allows Allogene to issue shares in a timely manner as market conditions permit, providing flexibility to support its clinical and commercial initiatives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.